Investigation Launched into Applied Therapeutics Over Federal Securities Violations

Glancy Prongay & Murray LLP Investigates Potential Legal Issues

Glancy Prongay & Murray LLP (“GPM”), a prominent national law firm focusing on shareholder rights, has announced an investigation regarding Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) APLT. This inquiry is centered on possible violations of federal securities laws that may have impacted investors.

Investors who believe they have suffered financial losses linked to Applied Therapeutics can find more information about pursuing claims under federal securities laws by visiting www.glancylaw.com/cases/applied-therapeutics-inc/. For inquiries, contact Charles H. Linehan at 310-201-9150, toll-free at 888-773-9224, or via email at [email protected].

Recent Challenges Faced by Applied Therapeutics

On November 27, 2024, Applied Therapeutics revealed that the U.S. Food and Drug Administration (“FDA”) had issued a Complete Response Letter (“CRL”) regarding its New Drug Application (“NDA”) for the drug govorestat, intended to treat Classic Galactosemia. The FDA determined that the application could not be approved in its current form due to deficiencies identified during its review.

The announcement of the CRL significantly affected the company’s stock, which plummeted by $6.54, or 76.3%, closing at $2.03 per share on November 29, 2024. This sharp decline highlights the potential impact of regulatory decisions on investor confidence.

Encouragement for Whistleblowers

Individuals with non-public information about Applied Therapeutics may consider assisting in the investigation or participating in the SEC Whistleblower Program. Whistleblowers providing original information could earn rewards of up to 30 percent of any successful recovery made by the SEC. For more details, interested parties should reach out to Charles H. Linehan at 310-201-9150, toll-free at 888-773-9224, or at [email protected].

About GPM

Glancy Prongay & Murray LLP specializes in representing investors and consumers in securities litigation and complex class actions. The firm has earned a strong reputation, consistently appearing in the annual SCAS Top 50 Report by ISS Securities Class Action Services. In 2018, GPM ranked among the top five law firms for the number of securities class action settlements and ranked sixth in total settlement amounts.

With four offices nationwide, GPM’s team of nearly 40 attorneys has achieved landmark rulings and secured billions of dollars for clients across various fields, including securities, antitrust, and consumer cases. The firm has handled numerous cases of corporate misconduct and has significant expertise in a wide spectrum of industries, from healthcare to technology. GPM’s noteworthy achievements have been reported by major news outlets like The Wall Street Journal, Bloomberg Businessweek, and Forbes.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212324063/en/